Cerebral Microbleeds and Macrobleeds: Should They Influence Our Recommendations for Antithrombotic Therapies?

Intracerebral hemorrhage (ICH, or macrobleeds) and cerebral microbleeds—smaller foci of hemosiderin deposits commonly detected by magnetic resonance imaging of older adults with or without ICH—are both associated with an increased risk of future ICH. These hemorrhagic pathologies also share risk fac...

Full description

Saved in:
Bibliographic Details
Published in:Current cardiology reports 2013-12, Vol.15 (12), p.425-425, Article 425
Main Authors: Haley, Kellen E., Greenberg, Steven M., Gurol, M. Edip
Format: Article
Language:English
Subjects:
Anticoagulants - adverse effects
Cardiology
Cerebral Amyloid Angiopathy - drug therapy
Cerebral Amyloid Angiopathy - epidemiology
Cerebral Amyloid Angiopathy - prevention & control
Cerebral Hemorrhage - epidemiology
Cerebral Hemorrhage - etiology
Cerebral Hemorrhage - prevention & control
Female
Functional Neuroimaging
Humans
Leukoencephalopathies - drug therapy
Leukoencephalopathies - epidemiology
Leukoencephalopathies - prevention & control
Male
Medicine
Medicine & Public Health
Patient Selection
Risk Factors
Section Editor
Siderosis - drug therapy
Siderosis - epidemiology
Siderosis - prevention & control
Stroke (C Sila
Stroke - complications
Stroke - drug therapy
Stroke - prevention & control
Topical Collection on Stroke
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intracerebral hemorrhage (ICH, or macrobleeds) and cerebral microbleeds—smaller foci of hemosiderin deposits commonly detected by magnetic resonance imaging of older adults with or without ICH—are both associated with an increased risk of future ICH. These hemorrhagic pathologies also share risk factors with ischemic thromboembolic conditions that may require antithrombotic therapy, requiring specialists in cardiology, internal medicine, and neurology to weigh the benefits vs hemorrhagic risks of antithrombotics in individual patients. This paper will review recent advances in our understanding of hemorrhage prone cerebrovascular pathologies with a particular emphasis on use of these markers in decision making for antithrombotic use.
ISSN:1523-3782
1534-3170
DOI:10.1007/s11886-013-0425-8